Calamos Convertible and High Income Fund

CHY · NASDAQ

$11.12−$0.105 (−0.94%)TodayMarket closed ·
Prev close $11.22

About CHY

Calamos Convertible and High Income Fund is a US-based company operating in industry. The company is headquartered in Naperville, Illinois. The company went IPO on 2003-05-28. Calamos Convertible and High Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is to provide total return through a combination of capital appreciation and current income. Under normal circumstances, the Fund invests at least 80% of its managed assets in a diversified portfolio of convertibles and below investment grade (high yield) non-convertible debt securities. The Fund invests at least 20% of its managed assets in convertible securities and at least 20% of its managed assets in below investment grade (high yield/high risk) non-convertible debt securities. The Fund invests in securities with a broad range of maturities. The average term to maturity of the Fund’s securities typically ranges from two to ten years. The Fund's derivative activities are focused on various derivatives, such as interest rate swaps, convertible securities and index options. The Fund's investment adviser is Calamos Advisors LLC.

Employees
0
Headquarters
Naperville, Illinois
Listed
May 28, 2003
Sector
N/A
Industry
N/A

Leadership

Calamos Convertible and High Income Fund executives
NameTitleSince
John Calamos—2003
Erik Ojala——
Daniel Dufresne——
Thomas Herman——
Thomas Kiley——
John Koudounis——
Stephen Atkins——
Mark Mickey——
John Neal——
Virginia Breen——
William Rybak——
Karen Stuckey——
Christopher Toub——
Lloyd Wennlund——

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.